Literature DB >> 24311631

Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors.

Annette B Håvik1, Guro E Lind, Hilde Honne, Torstein R Meling, David Scheie, Kirsten S Hall, Eva van den Berg, Fredrik Mertens, Piero Picci, Ragnhild A Lothe, Sverre Heim, Petter Brandal.   

Abstract

Entities:  

Keywords:  IDH1; IDH2; MPNST; glioblastoma; glioma

Mesh：

Substances：

Year:  2013        PMID： 24311631      PMCID： PMC3895390          DOI： 10.1093/neuonc/not230

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  19 in total

1.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Authors:  Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape
Journal:  Cancer Cell       Date:  2010-04-15       Impact factor: 31.743

2.  Analysis of the IDH1 codon 132 mutation in brain tumors.

Authors:  Jörg Balss; Jochen Meyer; Wolf Mueller; Andrey Korshunov; Christian Hartmann; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2008-11-05       Impact factor: 17.088

3.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

4.  Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.

Authors:  Mi Ran Kang; Min Sung Kim; Ji Eun Oh; Yoo Ri Kim; Sang Yong Song; Seong Il Seo; Ji Youl Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

5.  IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.

Authors:  Fonnet E Bleeker; Simona Lamba; Sieger Leenstra; Dirk Troost; Theo Hulsebos; W Peter Vandertop; Milo Frattini; Francesca Molinari; Margaret Knowles; Aniello Cerrato; Monica Rodolfo; Aldo Scarpa; Lara Felicioni; Fiamma Buttitta; Sara Malatesta; Antonio Marchetti; Alberto Bardelli
Journal:  Hum Mutat       Date:  2009-01       Impact factor: 4.878

6.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

7.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Authors:  Darrell R Borger; Kenneth K Tanabe; Kenneth C Fan; Hector U Lopez; Valeria R Fantin; Kimberly S Straley; David P Schenkein; Aram F Hezel; Marek Ancukiewicz; Hannah M Liebman; Eunice L Kwak; Jeffrey W Clark; David P Ryan; Vikram Deshpande; Dora Dias-Santagata; Leif W Ellisen; Andrew X Zhu; A John Iafrate
Journal:  Oncologist       Date:  2011-12-16       Impact factor: 5.837

8.  IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.

Authors:  A Pardanani; T L Lasho; C M Finke; M Mai; R F McClure; A Tefferi
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 12.883

9.  Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.

Authors:  P S Ward; J R Cross; C Lu; O Weigert; O Abel-Wahab; R L Levine; D M Weinstock; K A Sharp; C B Thompson
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 8.756

10.  IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.

Authors:  Rob A Cairns; Javeed Iqbal; François Lemonnier; Can Kucuk; Laurence de Leval; Jean-Philippe Jais; Marie Parrens; Antoine Martin; Luc Xerri; Pierre Brousset; Li Chong Chan; Wing-Chung Chan; Philippe Gaulard; Tak W Mak
Journal:  Blood       Date:  2012-01-03       Impact factor: 25.476
View more
  4 in total

1.  A novel truncated form of HMGA2 in tumors of the ovaries.

Authors:  Antonio Agostini; Ioannis Panagopoulos; Ben Davidson; Claes Goran Trope; Sverre Heim; Francesca Micci
Journal:  Oncol Lett       Date:  2016-06-29       Impact factor: 2.967

2.  5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma.

Authors:  Wioletta K Glowacka; Harshika Jain; Makiko Okura; Abulizi Maimaitiming; Yasin Mamatjan; Romina Nejad; Hamza Farooq; Michael D Taylor; Kenneth Aldape; Paul Kongkham
Journal:  Acta Neuropathol       Date:  2018-02-10       Impact factor: 15.887

3.  HMGA2 expression pattern and TERT mutations in tumors of the vulva.

Authors:  Antonio Agostini; Ioannis Panagopoulos; Hege Kilen Andersen; Lene Elisabeth Johannesen; Ben Davidson; Claes Göran Tropé; Sverre Heim; Francesca Micci
Journal:  Oncol Rep       Date:  2015-03-30       Impact factor: 4.136

4.  Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.

Authors:  Marine Jeanmougin; Annette B Håvik; Lina Cekaite; Petter Brandal; Anita Sveen; Torstein R Meling; Trude H Ågesen; David Scheie; Sverre Heim; Ragnhild A Lothe; Guro E Lind
Journal:  Mol Oncol       Date:  2020-04-04       Impact factor: 6.603
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.